N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 11.26 CNY -1.57%
Market Cap: 18.2B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Wall Street analysts forecast Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Nanjing King-friend Biochemical Pharmaceutical Co Ltd is 19.94 CNY with a low forecast of 17.17 CNY and a high forecast of 23.21 CNY.

Lowest Forecast
Wall Street Target
17.17 CNY
52% Upside
Average Forecast
Wall Street Target
19.94 CNY
77% Upside
Highest Forecast
Wall Street Target
23.21 CNY
106% Upside
Lowest
Price Target
17.17 CNY
52% Upside
Average
Price Target
19.94 CNY
77% Upside
Highest
Price Target
23.21 CNY
106% Upside
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors:
Price Targets
DMP
Dermapharm Holding SE
35% Upside
WVE
WAVE Life Sciences Ltd
265% Upside
ATAI
ATAI Life Sciences NV
283% Upside
ARVN
Arvinas Inc
187% Upside
DMP
Dermapharm Holding SE
35% Upside
WVE
WAVE Life Sciences Ltd
265% Upside
ATAI
ATAI Life Sciences NV
283% Upside
ARVN
Arvinas Inc
187% Upside
AUROPHARMA
Aurobindo Pharma Ltd
30% Upside
TBPH
Theravance Biopharma Inc
70% Upside
600085
Beijing Tongrentang Co Ltd
18% Upside
185750
Chong Kun Dang Pharmaceutical Corp
45% Upside

Revenue
Forecast

Revenue Estimate
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's revenue is 27%. The projected CAGR for the next 2 years is 28%.

27%
Past Growth
28%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's operating income is 28%. The projected CAGR for the next 2 years is 21%.

28%
Past Growth
21%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's net income is 16%. The projected CAGR for the next 2 years is 33%.

16%
Past Growth
33%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's stock price target?
Price Target
19.94 CNY

According to Wall Street analysts, the average 1-year price target for Nanjing King-friend Biochemical Pharmaceutical Co Ltd is 19.94 CNY with a low forecast of 17.17 CNY and a high forecast of 23.21 CNY.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
28%

For the last 8 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's revenue is 27%. The projected CAGR for the next 2 years is 28%.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
21%

For the last 8 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's operating income is 28%. The projected CAGR for the next 2 years is 21%.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
33%

For the last 8 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's net income is 16%. The projected CAGR for the next 2 years is 33%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.